{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:28:48Z","timestamp":1761920928360,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00520-021-06342-2","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T06:02:56Z","timestamp":1625551376000},"page":"8059-8067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis"],"prefix":"10.1007","volume":"29","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5350-2950","authenticated-orcid":false,"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"6342_CR1","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(11)61625-5","volume":"379","author":"R Peto","year":"2012","unstructured":"Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432\u2013444","journal-title":"Lancet"},{"key":"6342_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1200\/JCO.2007.11.3787","volume":"26","author":"M De Laurentiis","year":"2008","unstructured":"De Laurentiis M, Cancello G, D\u2019Agostino D, Giuliano M, Giordano A, Montagna E et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44\u201353","journal-title":"J Clin Oncol"},{"key":"6342_CR3","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/S0959-8049(00)00134-9","volume":"36","author":"JA Kramer","year":"2000","unstructured":"Kramer JA, Curran D, Piccart M, de Haes JC, Bruning PF, Klijn JG et al (2000) Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist. Eur J Cancer 36:1488\u20131497","journal-title":"Eur J Cancer"},{"key":"6342_CR4","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1093\/annonc\/mdn781","volume":"20","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Watanabe T, Minami H, Aogi K, Tabei T, Sano M et al (2009) Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802). Ann Oncol 20:1210\u20131215","journal-title":"Ann Oncol"},{"key":"6342_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","volume":"21","author":"GW Sledge","year":"2003","unstructured":"Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK et al (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588\u2013592","journal-title":"J Clin Oncol"},{"key":"6342_CR6","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ctrv.2014.02.001","volume":"40","author":"C Megerdichian","year":"2014","unstructured":"Megerdichian C, Olimpiadi Y, Hurvitz SA (2014) nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev 40:614\u2013625","journal-title":"Cancer Treat Rev"},{"key":"6342_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00520-019-04808-y","volume":"28","author":"Y Saito","year":"2020","unstructured":"Saito Y, Kobayashi M, Yamada T, Sakakibara-Konishi J, Shinagawa N, Kinoshita I et al (2020) Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome. Support Care Cancer 28:221\u2013227","journal-title":"Support Care Cancer"},{"key":"6342_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00520-017-3836-z","volume":"26","author":"N Chiu","year":"2018","unstructured":"Chiu N, Zhang L, Dent R, Giotis A, van Draanen J, Gallo-Hershberg D et al (2018) A prospective study of docetaxel-associated pain syndrome. Support Care Cancer 26:203\u2013211","journal-title":"Support Care Cancer"},{"key":"6342_CR9","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1007\/s00520-015-2941-0","volume":"24","author":"R Fernandes","year":"2016","unstructured":"Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B et al (2016) Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. Support Care Cancer 24:1583\u20131594","journal-title":"Support Care Cancer"},{"key":"6342_CR10","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1007\/s00520-016-3256-5","volume":"24","author":"R Fernandes","year":"2016","unstructured":"Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF et al (2016) Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer 24:3633\u20133650","journal-title":"Support Care Cancer"},{"key":"6342_CR11","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/bjc.1998.278","volume":"77","author":"H Kunitoh","year":"1998","unstructured":"Kunitoh H, Saijo N, Furuse K, Noda K, Ogawa M (1998) Neuromuscular toxicities of paclitaxel 210 mg m(-2) by 3-hour infusion. Br J Cancer 77:1686\u20131688","journal-title":"Br J Cancer"},{"key":"6342_CR12","first-page":"1","volume":"20","author":"EK Rowinsky","year":"1993","unstructured":"Rowinsky EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC (1993) Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20:1\u201315","journal-title":"Semin Oncol"},{"key":"6342_CR13","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","volume":"29","author":"CL Loprinzi","year":"2011","unstructured":"Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN et al (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472\u20131478","journal-title":"J Clin Oncol"},{"key":"6342_CR14","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1002\/cncr.27489","volume":"118","author":"BN Reeves","year":"2012","unstructured":"Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A et al (2012) Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer 118:5171\u20135178","journal-title":"Cancer"},{"key":"6342_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00520-019-04845-7","volume":"28","author":"R Asthana","year":"2020","unstructured":"Asthana R, Zhang L, Wan BA, Gallo-Hershberg D, Giotis A, Pasetka M et al (2020) Pain descriptors of taxane acute pain syndrome (TAPS) in breast cancer patients-a prospective clinical study. Support Care Cancer 28:589\u2013598","journal-title":"Support Care Cancer"},{"key":"6342_CR16","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/nm.2234","volume":"16","author":"K Ren","year":"2010","unstructured":"Ren K, Dubner R (2010) Interactions between the immune and nervous systems in pain. Nat Med 16:1267\u20131276","journal-title":"Nat Med"},{"key":"6342_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pharmthera.2005.06.003","volume":"109","author":"H Ueda","year":"2006","unstructured":"Ueda H (2006) Molecular mechanisms of neuropathic painphenotypic switch and initiation mechanisms. Pharmacol Ther 109:57\u201377","journal-title":"Pharmacol Ther"},{"key":"6342_CR18","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s00520-018-4571-9","volume":"27","author":"Y Kanbayashi","year":"2019","unstructured":"Kanbayashi Y, Sakaguchi K, Nakatsukasa K, Ouchi Y, Tabuchi Y, Yoshioka T et al (2019) Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis. Support Care Cancer 27:2673\u20132677","journal-title":"Support Care Cancer"},{"key":"6342_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/gyno.1998.5226","volume":"72","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1999) Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol 72:100\u2013101","journal-title":"Gynecol Oncol"},{"key":"6342_CR20","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00520-008-0508-z","volume":"17","author":"T Yoshida","year":"2009","unstructured":"Yoshida T, Sawa T, Ishiguro T, Horiba A, Minatoguchi S, Fujiwara H (2009) The efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following carboplatin and paclitaxel combination chemotherapy for non-small cell lung cancer. Support Care Cancer 17:315\u2013320","journal-title":"Support Care Cancer"},{"key":"6342_CR21","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.2004.99.298","volume":"22","author":"VH Nguyen","year":"2004","unstructured":"Nguyen VH, Lawrence HJ (2004) Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol 22:1767\u20131769","journal-title":"J Clin Oncol"},{"key":"6342_CR22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1177\/1078155215627502","volume":"23","author":"N Chiu","year":"2017","unstructured":"Chiu N, Chiu L, Chow R, Lam H, Verma S, Pasetka M et al (2017) Taxane-induced arthralgia and myalgia: a literature review. J Oncol Pharm Pract 23:56\u201367","journal-title":"J Oncol Pharm Pract"},{"key":"6342_CR23","first-page":"274","volume":"1","author":"SD Jacobson","year":"2003","unstructured":"Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH et al (2003) Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol 1:274\u2013278","journal-title":"J Support Oncol"},{"key":"6342_CR24","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178\u20131184","journal-title":"J Clin Oncol"},{"key":"6342_CR25","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1634\/theoncologist.12-12-1416","volume":"12","author":"L Balducci","year":"2007","unstructured":"Balducci L, Al-Halawani H, Charu V, Tam J, Shahin S, Dreiling L et al (2007) Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 12:1416\u20131424","journal-title":"Oncologist"},{"key":"6342_CR26","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1185\/030079907X219599","volume":"23","author":"L Pinto","year":"2007","unstructured":"Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283\u20132295","journal-title":"Curr Med Res Opin"},{"key":"6342_CR27","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404","journal-title":"BMC Cancer"},{"key":"6342_CR28","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ et al (2015) Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33:3199\u20133212","journal-title":"J Clin Oncol"},{"key":"6342_CR29","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663\u20131671","journal-title":"N Engl J Med"},{"key":"6342_CR30","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431\u20131439","journal-title":"J Clin Oncol"},{"key":"6342_CR31","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","volume":"24","author":"SE Jones","year":"2006","unstructured":"Jones SE, Savin MA, Holmes FA, O\u2019Shaughnessy JA, Blum JL, Vukelja S et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381\u20135387","journal-title":"J Clin Oncol"},{"key":"6342_CR32","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","volume":"89","author":"M Lambertini","year":"2014","unstructured":"Lambertini M, Del Mastro L, Bellodi A, Pronzato P (2014) The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 89:112\u2013128","journal-title":"Crit Rev Oncol Hematol"},{"key":"6342_CR33","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/1060028017706373","volume":"51","author":"DC Moore","year":"2017","unstructured":"Moore DC, Pellegrino AE (2017) Pegfilgrastim-induced bone pain: a review on incidence, risk factors, and evidence-based management. Ann Pharmacother 51:797\u2013803","journal-title":"Ann Pharmacother"},{"key":"6342_CR34","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00520-014-2597-1","volume":"23","author":"Y Kosaka","year":"2015","unstructured":"Kosaka Y, Rai Y, Masuda N, Takano T, Saeki T, Nakamura S et al (2015) Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer 23:1137\u20134311","journal-title":"Support Care Cancer"},{"key":"6342_CR35","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1548-5315(11)70402-8","volume":"7","author":"SA Gregory","year":"2010","unstructured":"Gregory SA, Schwartzberg LS, Mo M, Sierra J, Vogel C (2010) Evaluation of reported bone pain in cancer patients receiving chemotherapy in pegfilgrastim clinical trials: a retrospective analysis. Comm Oncol 7:297\u2013308","journal-title":"Comm Oncol"},{"key":"6342_CR36","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00520-015-2834-2","volume":"24","author":"H Xu","year":"2016","unstructured":"Xu H, Gong Q, Vogl FD, Reiner M, Page JH (2016) Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim. Support Care Cancer 24:723\u2013730","journal-title":"Support Care Cancer"},{"key":"6342_CR37","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.1007\/s00520-016-3119-0","volume":"24","author":"J Moukharskaya","year":"2016","unstructured":"Moukharskaya J, Abrams DM, Ashikaga T, Khan F, Schwartz J, Wilson K et al (2016) Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim. Support Care Cancer 24:3085\u20133093","journal-title":"Support Care Cancer"},{"key":"6342_CR38","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00520-016-3465-y","volume":"25","author":"E Gavioli","year":"2017","unstructured":"Gavioli E, Abrams M (2017) Prevention of granulocyte-colony stimulating factor (G-CSF) induced bone pain using double histamine blockade. Support Care Cancer 25:817\u2013822","journal-title":"Support Care Cancer"},{"key":"6342_CR39","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc2843","volume":"10","author":"D Metcalf","year":"2010","unstructured":"Metcalf D (2010) The colony-stimulating factors and cancer. Nat Rev Cancer 10:425\u2013434","journal-title":"Nat Rev Cancer"},{"key":"6342_CR40","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2011.37.8364","volume":"30","author":"JJ Kirshner","year":"2012","unstructured":"Kirshner JJ, Heckler CE, Janelsins MC, Dakhil SR, Hopkins JO, Coles C et al (2012) Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the university of rochester cancer center clinical community oncology program research base. J Clin Oncol 30:1974\u20131979","journal-title":"J Clin Oncol"},{"key":"6342_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0749-0690(05)70079-3","volume":"17","author":"SJ Gibson","year":"2001","unstructured":"Gibson SJ, Helme RD (2001) Age-related differences in pain perception and report. Clin Geriatr Med 17:433\u2013456","journal-title":"Clin Geriatr Med"},{"key":"6342_CR42","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10147-015-0786-7","volume":"20","author":"K Tamura","year":"2015","unstructured":"Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H et al (2015) Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol 20:855\u2013865","journal-title":"Int J Clin Oncol"},{"key":"6342_CR43","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1007\/s00520-010-1042-3","volume":"19","author":"M Majem","year":"2011","unstructured":"Majem M, Moreno ME, Calvo N, Feliu A, P\u00e9rez J, Mangues MA (2011) Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. Support Care Cancer 19:1983\u20131990","journal-title":"Support Care Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06342-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-021-06342-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-021-06342-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T22:07:28Z","timestamp":1675548448000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-021-06342-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6342"],"URL":"https:\/\/doi.org\/10.1007\/s00520-021-06342-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the procedures performed in studies involving human participants were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this type of study, formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}